Fluorescence-Quenched Substrates for Live Cell Imaging of Human Glucocerebrosidase Activity
- 5 January 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 137 (3) , 1181-1189
Abstract
Deficiency of the lysosomal glycoside hydrolase glucocerebrosidase (GCase) leads to abnormal accumulation of glucosyl ceramide in lysosomes and the development of the lysosomal storage disease known as Gaucher’s disease. More recently, mutations in the GBA1 gene that encodes GCase have been uncovered as a major genetic risk factor for Parkinson’s disease (PD). Current therapeutic strategies to increase GCase activity in lysosomes involve enzyme replacement therapy (ERT) and molecular chaperone therapy. One challenge associated with developing and optimizing these therapies is the difficulty in determining levels of GCase activity present within the lysosomes of live cells. Indeed, visualizing the activity of endogenous levels of any glycoside hydrolases, including GCase, has proven problematic within live mammalian cells. Here we describe the successful modular design and synthesis of fluorescence-quenched substrates for GCase. The selection of a suitable fluorophore and quencher pair permits the generation of substrates that allow convenient time-dependent monitoring of endogenous GCase activity within cells as well as localization of activity within lysosomes. These efficiently quenched (∼99.9%) fluorescent substrates also permit assessment of GCase inhibition in live cells by either confocal microscopy or high content imaging. Such substrates should enable improved understanding of GCase in situ as well the optimization of small-molecule chaperones for this enzyme. These findings also suggest routes to generate fluorescence-quenched substrates for other mammalian glycoside hydrolases for use in live cell imaging.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada (RGPIN 298406)
This publication has 43 references indexed in Scilit:
- The carbohydrate-active enzymes database (CAZy) in 2013Nucleic Acids Research, 2013
- Gaucher disease paradigm: From ERAD to comorbidityHuman Mutation, 2012
- Phenotype, diagnosis, and treatment of Gaucher's diseaseThe Lancet, 2008
- Enzyme Replacement for Lysosomal DiseasesAnnual Review of Medicine, 2006
- Neuropathology provides clues to the pathophysiology of Gaucher diseaseMolecular Genetics and Metabolism, 2004
- Twin pairs showing discordance of phenotype in adult Gaucher's diseaseQJM: An International Journal of Medicine, 2004
- Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher diseaseProceedings of the National Academy of Sciences, 2002
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitorNature Medicine, 1999
- Occurrence of Parkinson's syndrome in type 1 Gaucher diseaseQJM: An International Journal of Medicine, 1996